Abstract: A semiconductor wafer held by a holding part in a chamber is irradiated and heated with halogen light emitted from a plurality of halogen lamps. A cylindrical louver and an annular light-shielding member, both made of opaque quartz, are provided between the halogen lamps and the semiconductor wafer. The outer diameter of the light-shielding member is smaller than the inner diameter of the louver. Light emitted from the halogen lamps and passing through a clearance between the inner wall surface of the louver and the outer circumference of the light-shielding member is applied to a peripheral portion of the semiconductor wafer where a temperature drop is likely to occur. On the other hand, light travelling toward an overheat region that has a higher temperature than the other region and appears in the surface of the semiconductor wafer when only a louver is installed is blocked off by the light-shielding member.

Abstract: A vehicle traveling control apparatus for a vehicle identifies a mobile object as a crossing mobile object if the supplementary angle of the angle formed between the velocity vector of the mobile object and the traveling direction of the vehicle is greater than a threshold. In a case where the supplementary angle was equal to or less than the threshold before the identification as the crossing mobile object and where a lateral position of the crossing mobile object is equal to or less than a distance threshold at the time of the identification, or in a case where the size of the crossing mobile object has been less than a predetermined value for a predetermined period of time or longer and where the lateral position is equal to or less than the distance threshold at the time of the identification, the crossing mobile object is excluded from emergency braking targets.

Abstract: A vehicle traveling control apparatus for a vehicle identifies a mobile object as a crossing mobile object if the supplementary angle of the angle formed between the velocity vector of the mobile object and the traveling direction of the vehicle is greater than a threshold. In a case where the supplementary angle was equal to or less than the threshold before the identification as the crossing mobile object and where a lateral position of the crossing mobile object is equal to or less than a distance threshold at the time of the identification, or in a case where the size of the crossing mobile object has been less than a predetermined value for a predetermined period of time or longer and where the lateral position is equal to or less than the distance threshold at the time of the identification, the crossing mobile object is excluded from emergency braking targets.

Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.

Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.

Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.

Abstract: A compound expressed by any one of Structural Formulas (1) to (13), a method for producing the same, and a compound-containing composition, an anti-cancer agent, and an anti-Helicobacter pylori agent each containing the above compound.

Abstract: A compound expressed by any one of Structural Formulas (1) to (13), a method for producing the same, and a compound-containing composition, an anti-cancer agent, and an anti-Helicobacter pylori agent each containing the above compound.

Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.

Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.